Alzheimer’s Prevention & Early Intervention

Alzheimer’s disease is not a sudden event. It is a slow cascade that unfolds over decades. The amyloid hypothesis— still the dominant framework despite legitimate debate— holds that misfolded amyloid-beta peptides begin aggregating into extracellular plaques years before any measurable cognitive symptom. These plaques trigger a downstream sequence: hyperphosphorylation of tau protein, formation of intracellular neurofibrillary tangles, chronic microglial activation, synaptic loss, and eventually neuronal death.

Jack and colleagues published a landmark biomarker model in The Lancet Neurology in 2013 that mapped this progression quantitatively. Amyloid deposition becomes detectable on PET imaging fifteen to twenty years before symptom onset. Tau pathology follows. Synaptic dysfunction and neurodegeneration accelerate as both pathologies converge. By the time a patient presents with clinical dementia, the underlying damage is advanced and largely irreversible.

Braak staging describes how tau pathology spreads through the brain in a predictable anatomical sequence—beginning in the entorhinal cortex, moving into the hippocampus and limbic structures, and eventually reaching the neocortex. Each stage corresponds to increasing clinical severity. The critical insight is that stages I and II are often clinically silent. Pathology is present, but the brain’s compensatory reserves mask it.

Neuroinflammation is not a bystander in this process. Activated microglia and elevated pro-inflammatory cytokines—IL-1 beta, TNF-alpha, IL-6—accelerate both amyloid aggregation and tau propagation. The inflammatory component represents a modifiable target. So does the metabolic environment in which these pathologies develop.

Alzheimer’s disease does not develop in a metabolic vacuum. Insulin resistance, chronic systemic inflammation, oxidative stress, and nutrient deficiencies all contribute to an environment in which amyloid and tau pathology accelerate. Addressing these contributors does not eliminate the disease, but it removes the metabolic accelerants that make it worse.

Suzanne de la Monte and colleagues at Brown University published research describing Alzheimer’s as a form of brain-specific insulin resistance—a concept they termed “type 3 diabetes.” Impaired insulin signaling in the brain reduces glucose uptake in neurons, increases oxidative damage, and promotes tau hyperphosphorylation. Patients with type 2 diabetes carry roughly double the risk of developing Alzheimer’s disease, and even prediabetic insulin resistance measurably increases vulnerability.

Dale Bredesen’s 2014 work on the reversal of cognitive decline introduced a framework for identifying the multiple metabolic and inflammatory contributors that converge in each individual patient. His protocol categorized subtypes of cognitive decline—inflammatory, atrophic, glycotoxic, toxic—and proposed that addressing the specific contributors driving each patient’s decline could produce measurable improvement. The approach has its critics, and we are careful about the word “reversal.” But the underlying logic is sound: a brain under metabolic siege degenerates faster than one that is metabolically supported.

Elevated homocysteine, low vitamin D, poor omega-3 status, disrupted sleep architecture, and chronic psychological stress each carry independent associations with accelerated cognitive decline. They are also modifiable. Our diagnostic panels measure these variables because they represent actionable targets—not because optimizing them constitutes a cure.